SX-682
As of the edition of 20 October 2026, SX-682 is a small molecule: in active development; acts on CXCR1 and CXCR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 14, 0 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Blood and lymph; Hormones; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 0 | 5 | 0 |
| Phase 2 | 9 | 1 | 8 | 0 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Syntrix Biosystems | Lead sponsor of trials | 2019 to now |